Absci (ABSI) vs Ultragenyx Pharmaceutical (RARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Absci (ABSI) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, gaining 153.4% versus a loss of 51.1%. Over five years, ABSI leads with a -4.4% price change compared with -80.7% for RARE. Absci is the larger company by market cap ($1.74 billion vs $1.53 billion), about 1.1 times the size, while Ultragenyx Pharmaceutical is growing revenue faster (+20.2% vs -38.2%).
Ultragenyx Pharmaceutical converts more of its revenue into profit, with a net margin of -85.4% versus -4113.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | RARE |
|---|---|---|
| Share price | $10.16 | $15.48 |
| Market cap | $1.74B | $1.53B |
| 1-day change | +13.65% | +1.24% |
| YTD return | +191.12% | -32.70% |
| 1-year return | +153.37% | -51.11% |
| 5-year return | -4.42% | -80.65% |
| Forward P/E | — | 22.87 |
| EPS (TTM) | $-0.79 | $-5.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.80M | $673.00M |
| Revenue growth (YoY) | -38.24% | +20.18% |
| Net income (latest FY) | $-115.18M | $-575.00M |
| Operating margin | -4297.04% | -79.49% |
| Net margin | -4113.68% | -85.44% |
| 52-week high | $12.06 | $39.89 |
| 52-week low | $2.24 | $12.73 |
| Distance from 52-week high | -15.72% | -61.19% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +41.73% | +73.06% |
| Average volume | 3.43M | 3.90M |
| Shares outstanding | 171.61M | 98.59M |
| Employees | 140 | 1,371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABSI has outperformed RARE by 204.5 percentage points over the past year.
- Ultragenyx Pharmaceutical is more profitable, keeping -85.4 cents of every revenue dollar as net income versus -4113.7 cents for Absci.
- Ultragenyx Pharmaceutical grew revenue faster in its latest fiscal year (+20.18% vs -38.24%).
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
ABSI vs RARE FAQ
Which is bigger, Absci or Ultragenyx Pharmaceutical?
Absci (ABSI) is larger, with a market capitalization of $1.74B compared with $1.53B for Ultragenyx Pharmaceutical (RARE).
Which stock has performed better over the past year, ABSI or RARE?
ABSI returned +153.37% over the past 12 months, compared with -51.11% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are Absci and Ultragenyx Pharmaceutical in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for Absci and Biotechnology: Pharmaceutical Preparations for Ultragenyx Pharmaceutical.